Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 13/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gpi-1485 SCHEMBL2006950 | 0.90 | FKBP1A (0.66) | FKBP1A | |
| Gpi-1485 SCHEMBL3568704 | 0.90 | FKBP1A (0.66) | FKBP1A | |
| SCHEMBL499064 | 0.89 | FKBP1A (0.72) | FKBP1A | |
| SCHEMBL4675555 | 0.89 | FKBP1A (0.72) | FKBP1A | |
| SCHEMBL5966171 | 0.89 | FKBP1A (0.72) | FKBP1A | |
| Trifluoroacetic Acid SCHEMBL499188 | 0.83 | FKBP1A (0.64) | FKBP1A | |
| SCHEMBL7250340 | 0.83 | FKBP1A (0.82) | FKBP1A | |
| SCHEMBL7255035 | 0.82 | FKBP1A (0.43) | FKBP1A | |
| SCHEMBL4675854 | 0.78 | FKBP1A (0.63) | FKBP1A | |
| SCHEMBL5275878 | 0.78 | FKBP1A (0.63) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153951-A1 | Neurotrophic pyrrolidines and piperidines, and related compositions and methods | KANOJIA RAMESH M (US) | 2005-07-14 | — | — | US | disclosed |
| US-6809107-B1 | NEURODEGENERATIVE DISEASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-10-26 | — | — | US | disclosed |
| US-6544976-B1 | Treating disorders characterized by neuronal damage caused by disease or trauma, such as Parkinson's disease, Alzheimer's disease, stroke, multiple sclerosis, amyotrophic lateral sclerosis, diabetic neuropathy and Bell's palsy. | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-08 | — | — | US | disclosed |
| EP-1202990-A2 | NEUROTROPHIC PYRROLIDINES AND PIPERIDINES, AND RELATED COMPOSITIONS CONTAINING THEM | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001004116-A2 | NEUROTROPHIC PYRROLIDINES AND PIPERIDINES, AND RELATED COMPOSITIONS CONTAINING THEM | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153951-A1 | Neurotrophic pyrrolidines and piperidines, and related compositions and methods | BDNF, NTRK2, NGF | FKBP1A 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.